ARCHIVES

Studies Question PSA Screening: PLCO Trial Finds No Survival Advantage, European Trial Finds Benefit At High Cost

This article is from The Cancer Letter archive.

Vol. 35 No. 11 | March 20, 2009

Download PDF Visit The Full Archive

Related Articles

DCT Board Okays New Surgery RFA, Will Hear Request For Support Of 30 Surgical Centers

April 11, 1980

NIH Advisors Urge Stronger Peer Review, Clinical Center Renewal

May 20, 1994

ODAC Votes For Accelerated Approval For Adcetris For Two Lymphoma Indications

July 22, 2011

Is $45 Million Too Much to Spend on PR? NCAB Panel Weighs NCI Communications Budget

December 7, 2012

50-Gene Set Identifies Known Types Of Breast Cancer

February 27, 2009

ODAC Meets at ASCO, Recommends Approval Of Dasatinib For CML.

June 9, 2006